Congenital adrenal hyperplasia
This page contains general information about Congenital adrenal hyperplasia. For more information on specific types, please visit the pages on 21-hydroxylase deficiency, 17a-Hydroxylase deficiency, 11β-hydroxylase deficiency, 3-beta-hydroxysteroid dehydrogenase, Cytochrome P450-oxidoreductase (POR) deficiency (ORD), congenital lipoid adrenal hyperplasia, cholesterol side-chain cleavage enzyme deficiency .
Congenital adrenal hyperplasia main page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Synonyms and keywords: Congenital adrenal hyperplasia, CAH, Adrenal hyperplasia
Overview
Classification
Congenital adrenal hyperplasia is classified into seven types based on the genetic causes that lead to hyperplasia and hormonal imbalance.
Disease | History and symptoms | Laboratory findings | Additional findings | ||
---|---|---|---|---|---|
Blood pressure | Genitalia | ||||
21-hydroxylase deficiency | Classic type |
|
|
||
Non-classic type |
|
|
|||
17a-Hydroxylase deficiency | |||||
11β-hydroxylase deficiency | |||||
3-beta-hydroxysteroid dehydrogenase | |||||
Cytochrome P450-oxidoreductase (POR) deficiency (ORD) | |||||
Congenital lipoid adrenal hyperplasia | |||||
Cholesterol side-chain cleavage enzyme deficiency |
Complications
- ==Screening==
Diagnosis
Criteria for the diagnosis of diabetes |
---|
FPG ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 h. |
OR |
2-h Plasma Glucose (PG) ≥200 mg/dL (11.1 mmol/L) during an OGTT. The test should be performed as described
by the WHO, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water. |
OR |
A1C ≥6.5% (48 mmol/mol). |
OR |
In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dL (11.1 mmol/L). |
Gestational diabetes
There are 2 strategies to confirm the GDM diagnosis.
- One-step 75-g Oral glucose tolerance test (OGTT)
- OR
- Two-step approach with a 50-g (nonfasting) screen followed by a 100-g OGTT for those who screen positive.[1]
One Step Strategy=
Perform a 75 g glucose tolerance test in 24-28 weeks of pregnancy and read the measures 1 h and 2 h after glucose ingestion as well as fasting glucose.[1] The OGTT should be performed in the morning after an overnight fast of at least 8 h. The diagnosis of GDM is made when any of the following plasma glucose values are met or exceeded:
- Fasting: 92 mg/dL (5.1 mmol/L)
- 1 h: 180 mg/dL (10.0 mmol/L)
- 2 h: 153 mg/dL (8.5 mmol/L)
Two Step Strategy
In this approach, screening with a 1 h 50-g glucose load test (GLT) followed by a 3 h 100-g OGTT for those who screen positive.[2]
The diagnosis of GDM is made when at least 2 out of 4 measures of 3 h 100-g OGTT became abnormal.
- The following table summarizes the diagnostic approach for gestational diabetes.
Cut off (mg/dl) | ||||
---|---|---|---|---|
Fasting | 1 Hour | 2 Hour | 3 Hour | |
|
92 | 180 | 153 | ---- |
|
---- | 140 | ---- | ---- |
|
95 | 180 | 155 | 140 |
|
105 | 190 | 165 | 145 |
Prevention
Life style modification is the mainstay of prevention of diabetes mellitus. It includes, changes in diet, weight reduction and exercise. The strongest evidence for diabetes prevention comes from the Diabetes Prevention Program (DPP). The DPP demonstrated that an intensive lifestyle intervention could reduce the incidence of type 2 diabetes by 58% over 3 years.[5]
References
- ↑ 1.0 1.1 "Standards of Medical Care in Diabetes-2016 Abridged for Primary Care Providers". Clin Diabetes. 34 (1): 3–21. 2016. doi:10.2337/diaclin.34.1.3. PMID 26807004.
- ↑ "Professional Practice Committee for the Standards of Medical Care in Diabetes-2016". Diabetes Care. 39 Suppl 1: S107–8. 2016. doi:10.2337/dc16-S018. PMID 26696673.
- ↑ Carpenter MW, Coustan DR (1982). "Criteria for screening tests for gestational diabetes". Am. J. Obstet. Gynecol. 144 (7): 768–73. PMID 7148898.
- ↑ "Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group". Diabetes. 28 (12): 1039–57. 1979. PMID 510803.
- ↑ Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, Hämäläinen H, Härkönen P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J (2006). "Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study". Lancet. 368 (9548): 1673–9. doi:10.1016/S0140-6736(06)69701-8. PMID 17098085.